Immunotherapy drug Keytruda received FDA approval and showed benefit for treatment of colorectal cancer
https://www.facingourrisk.org/XRAY/keytruda-effective-in-treating-colorectal-cancer
Full article: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-first-line-treatment-msi-hdmmr-colorectal-cancer
In June 2020, the FDA approved Keytruda (pembrolizumab) as an initial therapy for advanced colorectal cancer. This approval was based on the results from the KEYNOTE-177 study. In this study, Keytruda was more successful than chemotherapy in delaying progression of certain types of colorectal cancers. (11/25/20)
Questions To Ask Your Health Care Provider
- What are the best drug options for treating my colorectal cancer?
- What are the side effects of my treatment drugs?
- Which biomarkers was my cancer tested for? What were the results?
- Is my cancer due to microsatellite instability or mismatch repair deficiency?
- Can you provide a copy of my biomarker test results?
- Do I meet criteria for genetic counseling and testing for an inherited mutation?
- Can you refer me to a genetic counselor?
- Should I consider a clinical trial?
Open Clinical Trials
The following studies enroll people with advanced colorectal cancer.
- NCT05217446: Studying a Combination of Three Drugs to Treat Previously Untreated Metastatic Colorectal Cancer with Certain Tumor Markers.This study investigates the effects of three drugs that are combined as treatment for previously untreated metastatic colorectal cancer.
- NCT03607890: Nivolumab and Relatlimab in Advanced MSI-H Cancers Resistant to Prior PD-(L)1 Inhibitor. This study evaluates the safety, effectiveness and tolerability of using the immunotherapy drugs nivolumab and relatlimab in patients with microsatellite instability high (MSI-H) solid tumors that were resistant to prior PD-(L)1 therapy.
- NCT05253651: Treatment of HER2-positive Colorectal Cancer as First Line Treatment in the Metastatic Setting. This study evaluates whether the drug Tukysa (tucatinib) combined with other cancer drugs is more effective than the standard-of-care treatment in people with HER2-positive colorectal cancer.
- NCT02997228: Chemotherapy, Bevacizumab, and/or Atezolizumab for dMMR / MSI-H Metastatic Colorectal Cancer (COMMIT Study). The effort compares the effectiveness of combining chemotherapy and immunotherapy with an immunotherapy drug alone.
- NCT04008030: Nivolumab, Nivolumab Plus Ipilimumab, or Chemotherapy for Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer. This study compares the combination of immunotherapy agents nivolumab (Opdivo) plus ipilimumab (Yervoy) in patients who have MSI-H or dMMR metastatic colorectal cancer versus with nivolumab alone or chemotherapy alone.
Several other clinical trials for patients with colorectal cancer can be found here.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.